![Business Of Biotech podcast](/assets/images/square.png)
We love to hear from our listeners. Send us a message.
Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine." To get a grip on the "generative biology" work it's doing and the AI/ML impact it anticipates in the discovery and development of therapeutics, as well as clinical trials, we sat down with veteran biotech builder Mike Nally, CEO at Generate and CEO-Partner at Flagship Pioneering.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Fler avsnitt från "Business Of Biotech"
Missa inte ett avsnitt av “Business Of Biotech” och prenumerera på det i GetPodcast-appen.